Eligibility Criteria for Zepbound (Tirzepatide)
Adults are eligible for Zepbound if they have a BMI ≥30 kg/m² OR a BMI ≥27 kg/m² with at least one weight-related comorbidity, and pharmacotherapy should be initiated concurrently with lifestyle interventions—not after lifestyle modification has "failed." 1
BMI Thresholds
- BMI ≥30 kg/m² (obesity) without comorbidities
- BMI ≥27 kg/m² with at least one weight-related complication
These thresholds align with FDA approval criteria for all anti-obesity medications 2, 3.
Required Weight-Related Comorbidities (for BMI 27-29.9 kg/m²)
Weight-related complications that qualify patients include:
- Metabolic: Type 2 diabetes, prediabetes, metabolic syndrome, dyslipidemia
- Cardiovascular: Hypertension, cardiovascular disease
- Respiratory: Obstructive sleep apnea, asthma/reactive airway disease
- Hepatic: Nonalcoholic fatty liver disease (NAFLD/NASH)
- Reproductive: Polycystic ovary syndrome, female infertility, male hypogonadism
- Musculoskeletal: Osteoarthritis
- Other: Gastroesophageal reflux disease, urinary stress incontinence, depression 3
Lifestyle Intervention Requirements
Critical distinction: Current guidelines recommend pharmacotherapy be used concurrently with intensive lifestyle interventions, not sequentially after lifestyle modification fails 1, 4, 1. The outdated approach of requiring documented lifestyle failure before prescribing medication has been replaced by a more integrated treatment model.
Lifestyle interventions should include:
- Reduced-calorie meal plan
- Physical activity (≥150 minutes/week moderate-intensity aerobic exercise)
- Behavioral modification support 2, 1
However, pharmacotherapy should be considered immediately in patients who:
- Require more urgent weight loss due to severe obesity
- Need greater weight loss to manage inadequately controlled complications
- Have obesity stage 2 (at least one severe complication) 4, 3
Contraindications
While the provided evidence does not include the complete FDA label contraindications for Zepbound specifically, general contraindications for GLP-1 receptor agonist-based therapies include:
- Pregnancy (Grade A contraindication) 3
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- History of pancreatitis (relative contraindication)
Women of reproductive potential must use appropriate contraception while on treatment 3.
Special Populations
Elderly (≥65 years): Not a contraindication; use with caution and monitor for sarcopenia and osteopenia 3
Cardiovascular disease: Unlike sympathomimetic agents (phentermine), tirzepatide and other GLP-1 agonists are safer alternatives in patients with CVD 2. Semaglutide has demonstrated cardiovascular benefit, and tirzepatide cardiovascular outcome trials are ongoing 5.
Type 2 diabetes: Tirzepatide is particularly effective in this population, with FDA approval for both obesity and diabetes treatment 5.
Treatment Continuation Criteria
Medication should be discontinued if:
- Less than 5% weight loss after 12 weeks at maintenance dose (for most anti-obesity medications) 2, 1, 3
- Less than 2 kg weight loss during first 4 weeks of treatment 1
For tirzepatide specifically, clinical trials showed mean weight reductions of 15-20.9% at 72 weeks, with 85-91% of participants achieving ≥5% weight loss 6. Real-world data confirms effectiveness with 85.8% achieving ≥5% weight loss at 6 months 7.
Dosing and Titration
Tirzepatide is initiated at 2.5 mg weekly and titrated monthly to a maximum of 15 mg weekly based on efficacy and tolerability 5. The FDA-approved maintenance doses are 5 mg, 10 mg, and 15 mg weekly. Slow dose escalation is essential to minimize gastrointestinal side effects 5.
Common Pitfalls to Avoid
- Do not delay pharmacotherapy waiting for lifestyle modification to "fail"—this outdated approach delays effective treatment
- Do not use tirzepatide as monotherapy—always combine with lifestyle interventions 2, 1, 4
- Do not prescribe in pregnancy or without contraception in women of reproductive potential 3
- Do not rush dose escalation—gastrointestinal side effects are dose-dependent and occur primarily during titration 5, 6